Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform. In return, ...
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery ...
A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...
A new study reveals that modifying the CUL5 gene enhances CAR-T cell therapy for leukemia and lymphoma. This improves cell ...
Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...
The Australian Government is listing Retevmo® (selpercatinib) on the Pharmaceutical Benefits Scheme (PBS) for the first time ...
AZoLifeSciences on MSN21h
Gene Delivery Systems: Viral vs. Non-Viral VectorsThis article examines viral and non-viral vectors in gene therapy, highlighting their mechanisms, advantages, and limitations ...
The LNP-mRNA modality is a novel approach that uses lipid nanoparticles to deliver messenger RNA into cells. The mRNA acts as ...
MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering focused company, recently announced the acquisition of SeQure DX Inc., a market leader in on-target and off-target editing assessment services ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback